Cancer cachexia and fat-muscle physiology

New England Journal of Medicine

Volumn 365, Issue 6, 2011, Pages 565-567

  Fearon, Kenneth C H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FAT; GLYCOPROTEIN; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ADIPOSE TISSUE; ADVANCED CANCER; ARTICLE; CACHEXIA; CANCER GROWTH; DIABETES MELLITUS; DISEASE ASSOCIATION; ENERGY METABOLISM; FOOD INTAKE; HUMAN; LIPID METABOLISM; LIPOLYSIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METABOLISM; SATELLITE CELL; SKELETAL MUSCLE; SURVIVAL; TREATMENT RESPONSE;

EID: 80051643493     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1106880     Document Type: Article

References (5)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95.
2. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-43.
3. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410.
4. Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011 June 16 (Epub ahead of print).
5. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-9.